Literature DB >> 21765658

Recent advances in the systemic therapy of breast cancer.

J T Cole1.   

Abstract

A number of advances have been made over the last decade in the systemic therapy of breast cancer, including 1) the introduction of the taxanes, paclitaxel and docetaxel, into the treatment regimes for both early and advanced breast cancer; 2) a greater understanding of the use of high-dose chemotherapy, supplemented with stem cell rescue; 3) the development of newer parenteral and oral chemotherapeutic drugs; 4) the first biologic therapy for breast cancer; 5) the first demonstration of effective drug therapy to prevent the development of breast cancer; and 6) effective agents to palliate and/or prevent complications from bone metastasis. These and other developments are allowing both the extension of life and a better quality of life for those stricken with the breast cancer.

Entities:  

Year:  2000        PMID: 21765658      PMCID: PMC3117550     

Source DB:  PubMed          Journal:  Ochsner J        ISSN: 1524-5012


  48 in total

1.  Application of a modification of the Polonovski reaction to the synthesis of vinblastine-type alkaloids.

Authors:  N Langlois; F Guéritte; Y Langlois; P Potier
Journal:  J Am Chem Soc       Date:  1976-10-27       Impact factor: 15.419

2.  The product of the human c-erbB-2 gene: a 185-kilodalton glycoprotein with tyrosine kinase activity.

Authors:  T Akiyama; C Sudo; H Ogawara; K Toyoshima; T Yamamoto
Journal:  Science       Date:  1986-06-27       Impact factor: 47.728

3.  Prospective randomized trial of docetaxel versus doxorubicin in patients with metastatic breast cancer.

Authors:  S Chan; K Friedrichs; D Noel; T Pintér; S Van Belle; D Vorobiof; R Duarte; M Gil Gil; I Bodrogi; E Murray; L Yelle; G von Minckwitz; S Korec; P Simmonds; F Buzzi; R González Mancha; G Richardson; E Walpole; M Ronzoni; M Murawsky; M Alakl; A Riva; J Crown
Journal:  J Clin Oncol       Date:  1999-08       Impact factor: 44.544

4.  Advanced breast cancer: a phase II trial with gemcitabine.

Authors:  J Carmichael; K Possinger; P Phillip; M Beykirch; H Kerr; J Walling; A L Harris
Journal:  J Clin Oncol       Date:  1995-11       Impact factor: 44.544

5.  Phase I trial of docetaxel administered by weekly infusion in patients with advanced refractory cancer.

Authors:  J D Hainsworth; H A Burris; J B Erland; M Thomas; F A Greco
Journal:  J Clin Oncol       Date:  1998-06       Impact factor: 44.544

6.  Effective second line chemotherapy of advanced breast cancer with navelbine and mitomycin C.

Authors:  W Scheithauer; G Kornek; K Haider; W Kwasny; T Schenk; R Pirker; D Depisch
Journal:  Breast Cancer Res Treat       Date:  1993       Impact factor: 4.872

7.  High-dose consolidation therapy with autologous stem-cell rescue in stage IV breast cancer: follow-up report.

Authors:  S F Williams; T Gilewski; R Mick; J D Bitran
Journal:  J Clin Oncol       Date:  1992-11       Impact factor: 44.544

8.  Mobilization of peripheral blood progenitor cells by chemotherapy and granulocyte-macrophage colony-stimulating factor for hematologic support after high-dose intensification for breast cancer.

Authors:  A D Elias; L Ayash; K C Anderson; M Hunt; C Wheeler; G Schwartz; I Tepler; R Mazanet; C Lynch; S Pap
Journal:  Blood       Date:  1992-06-01       Impact factor: 22.113

9.  Phase II trial of docetaxel in advanced anthracycline-resistant or anthracenedione-resistant breast cancer.

Authors:  P M Ravdin; H A Burris; G Cook; P Eisenberg; M Kane; W A Bierman; J Mortimer; E Genevois; R E Bellet
Journal:  J Clin Oncol       Date:  1995-12       Impact factor: 44.544

10.  Recombinant humanized anti-HER2 antibody (Herceptin) enhances the antitumor activity of paclitaxel and doxorubicin against HER2/neu overexpressing human breast cancer xenografts.

Authors:  J Baselga; L Norton; J Albanell; Y M Kim; J Mendelsohn
Journal:  Cancer Res       Date:  1998-07-01       Impact factor: 12.701

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.